tiprankstipranks
Trending News
More News >
Lantheus (LNTH)
NASDAQ:LNTH
US Market

Lantheus (LNTH) Earnings Dates, Call Summary & Reports

Compare
1,504 Followers

Earnings Data

Report Date
Apr 30, 2026
After Close (Confirmed)
Period Ending
2026 (Q1)
Consensus EPS Forecast
1.25
Last Year’s EPS
1.53
Same Quarter Last Year
Based on 6 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Feb 26, 2026|
% Change Since:
|
Earnings Call Sentiment|Neutral
Balanced / Neutral: The call highlighted meaningful strategic progress — acquisitions (Neuraceq, OCTEVY candidate), a broadened radiodiagnostic pipeline, strong product positions (PYLARIFY volumes, DEFINITY market share), multiple near-term regulatory milestones, and a clear commercialization plan targeting 2027 growth. However, near-term pressures are material: PYLARIFY revenue decline and pricing headwinds, gross margin compression (~289 bps YoY), Q4 cash-flow and free-cash-flow deterioration, and notable one-time integration and litigation costs. Management is taking prudent, deliberate steps (divestiture of SPECT, focusing capital on diagnostics, launch-readiness investments) which support a constructive medium-to-long-term outlook, but the near-term financial headwinds and execution/timing risks balance the positives.
Company Guidance
Lantheus guided 2026 worldwide net revenue of $1.40–$1.45 billion with gross margin near 65.5% and EPS of $5.00–$5.25 (based on ~66 million fully diluted shares), noting an effective tax rate of ~26% and expected net interest/other expense of about $5 million; R&D is planned at ~10–11% of revenue (up ~200 bps), G&A ~10% of revenue, and sales & marketing investment implied around the low‑teens (~12–12.5%) to support upcoming launches. Product and portfolio assumptions include PYLARIFY net revenue down 8%–10% in 2026 (higher volume but modest price erosion and a rolling Q4 transition to a new F‑18 formulation), Neuraceq expected to grow triple‑digits inorganically (Neuraceq contributed $31M in Q4 and $51.4M since acquisition), DEFINITY to grow low‑ to mid‑single digits (DEFINITY >$85M in Q4), and no meaningful commercial contribution from new approvals in 2026 with material impact expected in 2027; management also adjusted the 2025 comparable baseline to $1,424.2M after the SPECT divestiture ($111.4M) and one‑time items, cited a normalized EPS comparison of ~$5.75, and highlighted cash of $359.1M, Q4 operating cash flow of $90.2M and free cash flow of $81.4M, plus $100M of share repurchases in the quarter (leaving $200M authorization).
Revenue and Scale
Q4 2025 revenue of $406.8M, up 4% year-over-year; Full-year 2025 revenue of $1,541.6M, up 0.5% YoY. Company impacted ~7 million patients in 2025.
Strategic M&A and Portfolio Expansion
Completed acquisitions to diversify radiodiagnostic portfolio including commercialized Neuraceq (beta-amyloid PET) and OCTEVY (neuroendocrine PET candidate), and announced divestiture of legacy SPECT business effective Jan 1, 2026 to focus on PET radiodiagnostics.
Neuraceq Commercial Traction
Neuraceq contributed $31M in Q4 2025 and $51.4M since acquisition in late July; company expects Neuraceq to grow triple digits inorganically in 2026 as manufacturing footprint expands (six additional PMF sites planned).
Market-Leading Products
PYLARIFY remains market-leading in PSMA PET (volume up ~4% YoY in Q4); DEFINITY delivered >$85M in Q4 and holds >80% market share, expected to grow low- to mid-single digits in 2026.
Late-Stage Pipeline and Potential Approvals
Multiple near-term regulatory milestones in 2026: new PSMA PET formulation (PDUFA Mar 6), OCTEVY (PDUFA Mar 29), PNT2003 (radioequivalent to Lutathera) with pending Hatch-Waxman litigation decision mid-year, and MK-6240 (tau PET; PDUFA Aug 13). Management expects material commercialization impact beginning in 2027.
2026 Financial Outlook
Guidance for 2026 worldwide net revenue of $1.40B–$1.45B, gross margin ~65.5%, R&D 10%–11% of revenue, and EPS guidance of $5.00–$5.25, reflecting planned investments and launch preparation.
Operational & Reimbursement Strategy
Clear launch playbook: regional rolling transition to new F-18 PSMA formulation in Q4 2026 with focus on coding, transitional pass-through status, payer coverage, and PMF network continuity to minimize supply disruption and drive 2027 growth.
Capital Return and Balance Sheet Actions
Completed $100M share repurchase in Q4 (1.77M shares) with $200M authorization remaining; cash & cash equivalents (net) of $359.1M at year-end.

Lantheus (LNTH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

LNTH Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Apr 30, 2026
2026 (Q1)
1.25 / -
1.53
Feb 26, 2026
2025 (Q4)
1.19 / 1.67
1.595.03% (+0.08)
Nov 06, 2025
2025 (Q3)
1.26 / 1.27
1.7-25.29% (-0.43)
Aug 06, 2025
2025 (Q2)
1.68 / 1.57
1.8-12.78% (-0.23)
May 07, 2025
2025 (Q1)
1.66 / 1.53
1.69-9.47% (-0.16)
Feb 26, 2025
2024 (Q4)
1.54 / 1.59
1.75-9.14% (-0.16)
Nov 06, 2024
2024 (Q3)
1.56 / 1.70
1.4715.65% (+0.23)
Jul 31, 2024
2024 (Q2)
1.83 / 1.80
1.5416.88% (+0.26)
May 02, 2024
2024 (Q1)
1.54 / 1.69
1.4714.97% (+0.22)
Feb 22, 2024
2023 (Q4)
1.43 / 1.75
1.3727.74% (+0.38)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

LNTH Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 06, 2025
$57.23$53.69-6.19%
Aug 06, 2025
$72.63$51.87-28.58%
May 07, 2025
$104.84$80.49-23.23%
Feb 26, 2025
$80.05$93.25+16.49%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Lantheus (LNTH) report earnings?
Lantheus (LNTH) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
    What is Lantheus (LNTH) earnings time?
    Lantheus (LNTH) earnings time is at Apr 30, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is LNTH EPS forecast?
          LNTH EPS forecast for the fiscal quarter 2026 (Q1) is 1.25.

            Lantheus (LNTH) Earnings News

            Lantheus Blasts Up as Earnings Impress
            Premium
            Market News
            Lantheus Blasts Up as Earnings Impress
            3y ago